Show simple item record

dc.contributor.authorCowan, K
dc.contributor.authorAnichtchik, O
dc.contributor.authorLuo, S
dc.date.accessioned2021-10-19T11:24:24Z
dc.date.issued2019-07
dc.identifier.issn1080-563X
dc.identifier.issn1755-5949
dc.identifier.urihttp://hdl.handle.net/10026.1/18111
dc.description.abstract

<jats:title>Summary</jats:title><jats:p>The mitochondrion is a unique organelle with a diverse range of functions. Mitochondrial dysfunction is a key pathological process in several neurodegenerative diseases. Mitochondria are mostly important for energy production; however, they also have roles in Ca<jats:sup>2+</jats:sup> homeostasis, ROS production, and apoptosis. There are two major systems in place, which regulate mitochondrial integrity, mitochondrial dynamics, and mitophagy. These two processes remove damaged mitochondria from cells and protect the functional mitochondrial population. These quality control systems often become dysfunctional during neurodegenerative diseases, such as Parkinson's and Alzheimer's disease, causing mitochondrial dysfunction and severe neurological symptoms.</jats:p>

dc.format.extent825-836
dc.format.mediumPrint-Electronic
dc.languageen
dc.language.isoen
dc.publisherWiley
dc.subjectcytotoxicity
dc.subjectmitochondrion
dc.subjectmitophagy
dc.subjectneurodegeneration
dc.titleMitochondrial integrity in neurodegeneration
dc.typejournal-article
dc.typeReview
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/30746905
plymouth.issue7
plymouth.volume25
plymouth.publication-statusPublished
plymouth.journalCNS Neuroscience and Therapeutics
dc.identifier.doi10.1111/cns.13105
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
plymouth.organisational-group/Plymouth/Users by role/Researchers in ResearchFish submission
dc.publisher.placeEngland
dcterms.dateAccepted2018-12-25
dc.rights.embargodate2021-10-20
dc.identifier.eissn1755-5949
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1111/cns.13105
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2019-07
rioxxterms.typeJournal Article/Review
plymouth.funderTackling autophagy and apoptosis for the potential therapy of Huntington's Disease::MRC


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV